Neopride Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 10-07-2024
- Paid Up Capital ₹ 4.55 Cr
as on 10-07-2024
- Company Age 11 Year, 9 Months
- Last Filing with ROC 31 Mar 2021
- Revenue %
(FY 2020)
- Ebitda -24.81%
(FY 2020)
- Net Worth
- Total Assets 0.07%
(FY 2020)
About Neopride Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 4.55 Cr, as per Ministry of Corporate Affairs (MCA) records.
Goluguri Reddy, Goluguri Reddy, and Goluguri Reddy serve as directors at the Company.
- CIN/LLPIN
U74140AP2013PLC086653
- Company No.
086653
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
26 Mar 2013
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Visakhapatnam, Andhra Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Neopride Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Goluguri Reddy  | Director | 26-Mar-2013 | Current |
| Goluguri Reddy | Director | 26-Mar-2013 | Current |
| Goluguri Reddy | Director | 26-Mar-2013 | Current |
Financial Performance of Neopride Pharmaceuticals.
Neopride Pharmaceuticals Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Neopride Pharmaceuticals?
In 2019, Neopride Pharmaceuticals had a promoter holding of 1.10% and a public holding of 98.90%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Novelty Reddy And Reddy Motors Private LimitedActive 17 years 11 monthsGoluguri Reddy and Goluguri Reddy are mutual person
Nutrient Marine Foods LimitedActive 13 years 13 daysGoluguri Reddy and Goluguri Reddy are mutual person
- Nancy Industries LimitedActive 16 years 9 months
Goluguri Reddy, Goluguri Reddy and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Neopride Pharmaceuticals?
Unlock and access historical data on people associated with Neopride Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Neopride Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Neopride Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
